BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3967262)

  • 1. Melphalan: a potential new agent in the treatment of childhood rhabdomyosarcoma.
    Houghton JA; Cook RL; Lutz PJ; Houghton PJ
    Cancer Treat Rep; 1985 Jan; 69(1):91-6. PubMed ID: 3967262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy of childhood rhabdomyosarcomas growing as xenografts in immune-deprived mice.
    Houghton JA; Houghton PJ; Green AA
    Cancer Res; 1982 Feb; 42(2):535-9. PubMed ID: 7034923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
    Houghton PJ; Cheshire PJ; Hallman JC; Bissery MC; Mathieu-Boué A; Houghton JA
    Cancer Res; 1993 Jun; 53(12):2823-9. PubMed ID: 8504425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reciprocal cross-resistance in human rhabdomyosarcomas selected in vivo for primary resistance to vincristine and L-phenylalanine mustard.
    Horton JK; Houghton PJ; Houghton JA
    Cancer Res; 1987 Dec; 47(23):6288-93. PubMed ID: 2890432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
    Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
    Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Childhood rhabdomyosarcoma xenografts: responses to DNA-interacting agents and agents used in current clinical therapy.
    Houghton JA; Cook RL; Lutz PJ; Houghton PJ
    Eur J Cancer Clin Oncol; 1984 Jul; 20(7):955-60. PubMed ID: 6430707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion.
    Rosenberg MC; Colvin OM; Griffith OW; Bigner SH; Elion GB; Horton JK; Lilley E; Bigner DD; Friedman HS
    Cancer Res; 1989 Dec; 49(24 Pt 1):6917-22. PubMed ID: 2582434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of intrinsic sensitivity to Vinca alkaloids in xenografts of pediatric rhabdomyosarcomas.
    Houghton JA; Williams LG; Torrance PM; Houghton PJ
    Cancer Res; 1984 Feb; 44(2):582-90. PubMed ID: 6692363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft.
    Lilley ER; Rosenberg MC; Elion GB; Colvin OM; Bigner DD; Friedman HS
    Cancer Res; 1990 Jan; 50(2):284-7. PubMed ID: 2295068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth and characterization of childhood rhabdomyosarcomas as xenografts.
    Houghton JA; Houghton PJ; Webber BL
    J Natl Cancer Inst; 1982 Mar; 68(3):437-43. PubMed ID: 6950170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
    Houghton PJ; Cheshire PJ; Myers L; Stewart CF; Synold TW; Houghton JA
    Cancer Chemother Pharmacol; 1992; 31(3):229-39. PubMed ID: 1464161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
    Leggas M; Stewart CF; Woo MH; Fouladi M; Cheshire PJ; Peterson JK; Friedman HS; Billups C; Houghton PJ
    Clin Cancer Res; 2002 Sep; 8(9):3000-7. PubMed ID: 12231547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft.
    Laskowitz DT; Elion GB; Dewhirst MW; Griffith OW; Savina PM; Blum MR; Prescott DM; Bigner DD; Friedman HS
    Radiat Res; 1992 Feb; 129(2):218-23. PubMed ID: 1734453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of the cyclopropylpyrroloindole, carzelesin, against xenografts derived from adult and childhood solid tumors.
    Houghton PJ; Cheshire PJ; Hallman JD; Houghton JA
    Cancer Chemother Pharmacol; 1995; 36(1):45-52. PubMed ID: 7720175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
    Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma.
    Hazelton BJ; Houghton JA; Parham DM; Douglass EC; Torrance PM; Holt H; Houghton PJ
    Cancer Res; 1987 Aug; 47(16):4501-7. PubMed ID: 3607778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
    Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
    Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between experimentally and clinically demonstrated activity of two new cytotoxic agents in breast cancer.
    Bailey MJ; Smith IE
    Anticancer Res; 1985; 5(4):419-22. PubMed ID: 3839994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)-urea against xenografts of pediatric rhabdomyosarcoma.
    Houghton PJ; Houghton JA; Myers L; Cheshire P; Howbert JJ; Grindey GB
    Cancer Chemother Pharmacol; 1989; 25(2):84-8. PubMed ID: 2598403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of recombinant human insulin-like growth factor-I (rhIGF-I) on cell growth and cytotoxicity of drugs in childhood rhabdomyosarcoma cell lines and xenograft models.
    Gidding CE; Germain GS; Dilling MB; Meeuwsen-de Boer TG; Ashmun RA; de Graaf SS; Veverka KA; Kamps WA; Houghton PJ
    Cancer Chemother Pharmacol; 2000; 45(1):21-30. PubMed ID: 10647497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.